RT Conference Proceedings
T1 Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial
A1 Goss, G. D.
A1 Cobo, M.
A1 Lu, S.
A1 Syrigos, K.
A1 Lee, K. H.
A1 Goker, E.
A1 Georgoulias, V.
A1 Li, W.
A1 Isla, D.
A1 Morabito, A.
A1 Min, Y. J.
A1 Ardizzoni, A.
A1 Jian, H.
A1 Yu, Y.
A1 Bender, S.
A1 Cseh, A.
A1 Felip, E.
K1 lung SCC
K1 afatinib
K1 erlotinib
K1 second-line
PB Elsevier science inc
SN 1556-0864
YR 2019
FD 2019-11-01
LK https://hdl.handle.net/10668/24371
UL https://hdl.handle.net/10668/24371
LA en
DS RISalud
RD Apr 15, 2025